ÀÚµ¿·Î±×¾Æ¿ô¾È³»
ÀÚµ¿ ·Î±×¾Æ¿ô ³²Àº ½Ã°£ : 30ÃÊ
°í°´´ÔÀÇ ¾ÈÀüÇÑ Á¤º¸º¸¾ÈÀ» À§ÇØ ·Î±×ÀÎ ÈÄ ¾à10ºÐµ¿¾È ¼ºñ½º ÀÌ¿ëÀÌ ¾ø¾î ÀÚµ¿ ·Î±×¾Æ¿ô µË´Ï´Ù. ·Î±×ÀÎ ½Ã°£À» ¿¬ÀåÇϽðڽÀ´Ï´Ù?
ÀÚµ¿·Î±×¾Æ¿ô¾È³»
°í°´´ÔÀÇ ¾ÈÀüÇÑ Á¤º¸º¸¾ÈÀ» À§ÇØ ·Î±×ÀÎ ÈÄ ¾à10ºÐµ¿¾È ¼ºñ½º ÀÌ¿ëÀÌ ¾ø¾î ÀÚµ¿ ·Î±×¾Æ¿ô µÇ¾ú½À´Ï´Ù.
±¸ºÐ | ºÐ·ù | Ç׸ñ | °¡°ÝÁ¤º¸ (´ÜÀ§ : ¿ø) | ƯÀÌ»çÇ× | ÃÖÁ¾º¯°æÀÏ | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
¸íĪ | ÄÚµå | ±¸ºÐ | ºñ¿ë | ÃÖÀúºñ¿ë | ÃÖ´ëºñ¿ë | Ä¡·áÀç·á´ë Æ÷ÇÔ¿©ºÎ |
¾àÁ¦ºñ Æ÷ÇÔ¿©ºÎ |
||||
Ä¡°úóġ,¼ö¼ú·á | Ä¡¾ÆÁúȯ óġ | Onlay | UZ004 | 350,000 | 2021-11-30 | ||||||
°Ë»ç·á | ¾à¹° ¹× µ¶¹°°Ë»ç | Opiates (ºñ) | NPIS0003 | 11,640 | 2020-02-11 | ||||||
°Ë»ç·á | ºÐÀÚº´¸®°Ë»ç | PARK2 gene mutation | CZ620 | 600,600 | 2017-01-01 | ||||||
°Ë»ç·á | ºÐÀÚº´¸®°Ë»ç | PMS2 gene mutation (HNPCC, Hereditary non-polyposis colon cancer) | CZ581 | 535,350 | 2025-03-11 | ||||||
ÃÊÀ½ÆÄ | ³²¼º»ý½Ä±â | PROU | 45,100 | 2023-01-06 | |||||||
°Ë»ç·á | ºÐÀÚº´¸®°Ë»ç | PRSS1 gene mutation (Hereditary pancreatitis) | C5806 | 751,300 | 2024-01-23 | ||||||
Ä¡°úÀÇ º¸Ã¶·á | Ä¡°úÀÇ º¸Ã¶·á | Para Post[±â¼ºÇ°]::º¸»ó | NPIS0003 | 120,000 | 2022-01-01 | ||||||
°Ë»ç·á | ÀÚ°¡¸é¿ªÁúȯ°Ë»ç | Paraneoplastic autoAb(Á¤·®) | CZ422 | 261,800 | 2025-03-13 | ||||||
°Ë»ç·á | ÀÚ°¡¸é¿ªÁúȯ°Ë»ç | Paraneoplastic autoAb(Á¤¼º) | CZ422 | 223,220 | 2025-03-01 | ||||||
°Ë»ç·á | ¾à¹° ¹× µ¶¹°°Ë»ç | Phenylglyoxylic acid | 44,000 | 2017-01-01 | |||||||
ÃÊÀ½ÆÄ | ÃÊÀ½ÆÄ | Planning US for RF | EB442 | 119,800 | 2018-08-14 | ||||||
ÃÊÀ½ÆÄ | º¹ºÎ | Planning US for RF -°ú³»°Ë»ç | EB564 | 119,800 | 2022-01-10 | ||||||
°Ë»ç·á | ÃâÇ÷, Ç÷Àü °Ë»ç | Platelet Function test[Aspirin resistance] | 35,000 | 2017-01-01 | |||||||
ÃÊÀ½ÆÄ | ÃÊÀ½ÆÄ | Post-Biopsy US | EB448 | 121,300 | 2018-08-14 | ||||||
°Ë»ç·á | ¾à¹° ¹× µ¶¹°°Ë»ç | Procainamid-Á¤·®:Å©·Î¸¶Åä±×¶óÇǹý (ºñ) | 103,070 | 2017-01-01 |